Key Points of Coronary Artery Disease Studies in 2023:

• ORBITA-2: Confirmed PCI's role in relieving angina symptoms for stable patients.

• SELECT: Semaglutide (Ozempic) reduced cardiovascular events in overweight/obese patients with existing CVD.

• Left Main CAD Revascularization: Guidelines downgraded PCI to less strong recommendation for low-risk patients.

• ROMA-Women: Launched to study gender differences in CABG outcomes.

• New Chronic Coronary Disease Guidelines: Recommend SGLT2 inhibitors and GLP-1 agonists in select cases.

• REPRIEVE: Pitavastatin lowered cardiovascular risk in HIV patients on antiretroviral therapy.

• BIOVASC: Immediate PCI was safe and effective as staged procedures in ACS patients.

• Imaging Wars: ILLUMIEN IV showed a limited benefit of OCT, while RENOVATE-COMPLEX-PCI found value in complex cases.

• DAPT Duration: Studies suggest shorter regimens may be beneficial in certain patients.

• DAPA-MI: Mixed results for dapagliflozin in acute MI, but improved cardiometabolic outcomes.

• MINT: No harm seen with liberal transfusion strategy in anemic acute MI patients.

• Oral PCSK9 Inhibitor: Potential future breakthrough for LDL cholesterol control.